邮件订阅 RSS 中文 | English
高级检索

重组人血小板生成素在老年重症免疫性血小板减少症患者一线治疗中的短期疗效分析

Short-term efficacy of recombinant human thrombopoietin as first-line treatment in elderly patients with severe immune thrombocytopenia

    摘要
  • 摘要:
    目的 探讨重组人血小板生成素（recombinant human thrombopoietin，rhTPO）在老年重症原发免疫性血小板减少症（primary immune thrombocytopenia，ITP）患者一线治疗中的短期疗效。
    方法 回顾性选择2016年3月至2019年11月复旦大学附属中山医院青浦分院血液科和复旦大学附属金山医院血液科收治的36例老年（≥65岁）重症初治ITP患者，分为接受rhTPO联合经典一线方案治疗组（rhTPO组，n=22）和仅接受经典一线方案治疗组（对照组，n=14）。比较2组短期有效率、起效时间、血小板峰值、血小板达峰时间等，分析影响rhTPO疗效的相关因素。
    结果 rhTPO组和对照组的短期总有效率分别为100%（22/22）和92.9%（13/14），短期完全反应率分别为72.7%（16/22）和64.3%（9/14），差异均无统计学意义。但rhTPO组的中位起效时间显著短于对照组4.0（3.0，6.0）d vs 6.0（4.0，7.3）d，P=0.026。在未接受静脉输注免疫球蛋白和血小板输注的患者中，rhTPO组血小板峰值显著高于对照组。
    结论 rhTPO一线治疗可有效缩短老年重症ITP患者的起效时间，提高血小板计数。

     

    Abstract:
    Objective To explore the short-term efficacy of recombinant human thrombopoietin (rhTPO) as first-line treatment in elderly patients with severe primary immune thrombocytopenia (ITP).
    Methods From March 2016 to November 2019, 36 elderly patients (aged 65 years or above) with severe ITP were selected from the Department of Hematology, Qingpu Branch of Zhongshan Hospital, Fudan University and the Department of Hematology, Jinshan Hospital, Fudan University, patients were divided into rhTPO combined with classic first-line treatment group (rhTPO group, n=22) and only treated with classic first-line treatment group (control group, n=14). The short-term response rate, time to initial response, peak platelet counts, and time of peak platelet counts between two groups were compared and clinical characteristics possibly correlated with the efficacy of rhTPO were analyzed.
    Results The short-term overall response rates in the rhTPO group and control group were 100% (22/22) and 92.9% (13/14), respectively, and the short-term complete response rates were 72.7% (16/22) and 64.3% (9/14), respectively. However, the median time to initial response in the rhTPO group was significantly shorter than that in the control group4.0 (3.0, 6.0) d vs 6.0 (4.0, 7.3) d, P=0.026. In patients who did not receive intravenous immunoglobin and platelet transfusion, peak platelet counts in the rhTPO group were significantly higher than that in the control group(126.8±42.9)×109/L vs (79.3±42.0)×109/L, P=0.031.
    Conclusions First-line treatment combined with rhTPO effectively shortens the time to initial response and increases platelet counts in elderly patients with severe ITP.

     

    • HTML全文
    • 参考文献(12)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回